0001578563-24-000015.txt : 20240112
0001578563-24-000015.hdr.sgml : 20240112
20240112174645
ACCESSION NUMBER: 0001578563-24-000015
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20240111
FILED AS OF DATE: 20240112
DATE AS OF CHANGE: 20240112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOFFMAN LAWRENCE R
CENTRAL INDEX KEY: 0001211249
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34600
FILM NUMBER: 24533068
MAIL ADDRESS:
STREET 1: C/O COVALENT GROUP, INC.
STREET 2: 1275 DRUMMERS LANE, SUITE 100
CITY: WAYNE
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TENAX THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0000034956
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 262593535
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 GLEN LENNOX DRIVE
STREET 2: SUITE 300
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
BUSINESS PHONE: 919-855-2100
MAIL ADDRESS:
STREET 1: 101 GLEN LENNOX DRIVE
STREET 2: SUITE 300
CITY: CHAPEL HILL
STATE: NC
ZIP: 27517
FORMER COMPANY:
FORMER CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC.
DATE OF NAME CHANGE: 20080703
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC
DATE OF NAME CHANGE: 19920703
FORMER COMPANY:
FORMER CONFORMED NAME: SINEQUANON CORP
DATE OF NAME CHANGE: 19901219
3
1
primary_doc.xml
PRIMARY DOCUMENT
X0206
3
2024-01-11
0
0000034956
TENAX THERAPEUTICS, INC.
TENX
0001211249
HOFFMAN LAWRENCE R
101 GLEN LENNOX DRIVE, SUITE 300
CHAPEL HILL
NC
27517
0
1
0
0
Interim CFO
Common Stock
0
D
/s/ S. Halle Vakani, as Attorney-in-Fact
2024-01-12
EX-24
2
poalhoffman.txt
POA
POWER OF ATTORNEY
Known all by these presents, that the undersigned hereby
constitutes and appoints each of Donald R. Reynolds and S. Halle
Vakani, and each of them acting alone, signing singly, the undersigned's
true and lawful attorney-in-fact to: (1) execute for and on behalf of the
undersigned, in the undersigned's capacity as an officer, director and/or
10% or more stockholder of Tenax Therapeutics, Inc. (the "Company"),
Forms ID, 3, 4, 5, and Update Passphrase Acknowledgement (and any
amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "1934 Act") and
Schedules 13D and/or Schedules 13G (and any amendments thereto)
in accordance with the 1934 Act, and the rules promulgated
thereunder; (2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
and execute any such Form ID, 3, 4, 5, and Update Passphrase
Acknowledgement and Schedules 13D and/or Schedules 13G (and
any amendments thereto) and to file timely such form with the
United States Securities and Exchange Commission and any stock
exchange or similar authority; and (3) take any other action of any type
whatsoever in connection with the foregoing which in the opinion of such
attorney-in-fact may be of benefit to, in the best interest of, or
legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-
fact full power and authority to do and perform any and every
act and thing whatsoever requisite, necessary or proper to be
done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full
power of substitution or revocation, hereby ratifying and
confirming that all such attorneys-in-fact, or such attorneys-
in-facts' substitute or substitutes, shall lawfully do or
cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges
that the foregoing attorneys-in-fact, in serving in such
capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the 1934 Act.
The undersigned attests and agrees that the use of an electronic
signature in any authentication document that includes the
undersigned signatory's typed, conformed signature, and that is
filed with or furnished to the Securities and Exchange Commission
by or on behalf of the undersigned signatory, the Company or any
of its affiliates, constitutes the legal equivalent of the
undersigned signatory's manual signature for purposes of
authenticating the undersigned signatory's signature to any filing
or submission for which it is provided.
This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms
ID, 3, 4 and 5 and Schedules 13D and Schedules 13G with respect to the
undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to each of the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of this 10th day of January 2024.
/s/ Lawrence R. Hoffman
Lawrence R. Hoffman